# BioCryst Pharmaceuticals Inc. (BCRX)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $1.83B  
**Price:** $8.37 (+2.14%)

> BioCryst Pharmaceuticals Inc. is a biotechnology company specializing in the research, development, and commercialization of novel small-molecule drugs that target key enzymes in infectious and inflammatory diseases. Leveraging expertise in biology, computer modeling, and medicinal chemistry, the company focuses on structure-guided drug design to create oral therapeutics for difficult-to-treat rare diseases. Its pipeline and products address critical therapeutic areas, including hereditary angioedema, acute and uncomplicated seasonal influenza, filoviruses such as Ebola and Marburg viruses, and oncology. BioCryst Pharmaceuticals Inc. operates within the healthcare sector, particularly in drug manufacturing for specialty and generic applications, contributing to treatments for rare conditions and emerging infectious threats. Founded in 1986 and headquartered in Durham, North Carolina, it plays a vital role in advancing innovative therapies for underserved patient populations in the biopharmaceutical market.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $875M | $856M | $341M | $264M | — |
| 2024 | $451M | $438M | -$3M | -$89M | — |
| 2023 | $331M | $327M | -$104M | -$227M | — |
| 2022 | $271M | $264M | -$148M | -$247M | — |
| 2021 | $157M | $150M | -$178M | -$184M | — |
| 2020 | $18M | $16M | -$175M | -$183M | — |
| 2019 | $49M | $45M | -$99M | -$109M | — |
| 2018 | $21M | — | -$94M | -$101M | — |
| 2017 | $25M | $24M | -$57M | -$66M | — |
| 2016 | $26M | $24M | -$49M | -$55M | — |
| 2015 | $48M | $47M | -$39M | -$43M | — |
| 2014 | $14M | $14M | -$46M | -$45M | — |
| 2013 | $17M | — | -$31M | -$30M | — |
| 2012 | $26M | — | -$34M | -$39M | — |
| 2011 | $20M | — | -$50M | -$57M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $514M | $633M | -$119M | $90M | — |
| 2024 | $490M | $966M | -$476M | $105M | $315M |
| 2023 | $517M | $972M | -$456M | $111M | $303M |
| 2022 | $550M | $845M | -$295M | $305M | $232M |
| 2021 | $588M | $695M | -$107M | $504M | $298M |
| 2020 | $335M | $354M | -$19M | $272M | $123M |
| 2019 | $175M | $137M | $38M | $114M | $50M |
| 2018 | $147M | $98M | $49M | $27M | $30M |
| 2017 | $178M | $94M | $84M | $50M | $23M |
| 2016 | $90M | $88M | $2M | $22M | $23M |
| 2015 | $122M | $75M | $48M | $29M | — |
| 2014 | $137M | $61M | $76M | $55M | — |
| 2013 | $49M | $50M | -$1M | $21M | — |
| 2012 | $57M | $58M | -$454,000 | $21M | — |
| 2011 | $82M | $67M | $15M | $16M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $347M | — | — |
| 2024 | -$52M | — | — |
| 2023 | -$95M | — | — |
| 2022 | -$162M | — | — |
| 2021 | -$142M | — | — |
| 2020 | -$135M | — | — |
| 2019 | -$90M | $343,000 | -$90M |
| 2018 | -$93M | $366,000 | -$93M |
| 2017 | -$41M | $328,000 | -$41M |
| 2016 | -$53M | — | — |
| 2015 | -$13M | — | — |
| 2013 | -$27M | — | — |
| 2012 | -$37M | — | — |
| 2011 | -$32M | — | — |
| 2010 | -$29M | — | — |

Source: [CompaniesByCap](https://companiesbycap.com/company/BCRX)